000931.SHE Beijing Centergate Technologies Holding Co Ltd
- Market cap
- CNY 2.81B
- P/E
- -
- P/B
- 1.79x
- ROE
- -4.1%
- Dividend yield
- 0.17%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000931.SHE undervalued?
Graham numberThe Graham number of Beijing Centergate Technologies Holding Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Centergate Technologies Holding Co Ltd fundamental analysis
No fundamental analysis for Beijing Centergate Technologies Holding Co Ltd yet.
Beijing Centergate Technologies Holding Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Centergate Technologies Holding Co Ltd
Beijing Centergate Technologies (holding) Co., Ltd. engages in the production and sale of topical reagents, tablets, injections in China. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Naltrexone Hydrochloride tablets and injections to block the pharmacological effects of exogenous opioids; Acetaminophen and oxycodone tablets and injections for the treatment of moderate to severe pain; tramadol hydrochloride tablets and injections to…
Full company profileBeijing Centergate Technologies Holding Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Centergate Technologies Holding Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.48B | 1.74B | 1.77B | 2.14B | 1.79B | 1.96B | 2.06B | 2.28B | 2.53B | 2.44B | 2.00B |
| Gross Profit | 685M | 829M | 948M | 1.16B | 1.00B | 1.01B | 1.19B | 1.32B | 1.48B | 1.45B | 932M |
| Operating Income | 35.7M | 55.3M | 96.4M | 226M | 150M | 16.6M | 118M | 78.7M | 111M | 177M | 53.6M |
| EBITDA | 199M | 195M | 336M | 314M | 222M | 112M | 196M | 320M | 375M | 313M | 8.16M |
| Net Income | 27.4M | 14.3M | 93.1M | 95.2M | 55.4M | -100M | -30.2M | 48.6M | 53.6M | 47.9M | -64.0M |
| EPS | 0.04 | 0.02 | 0.12 | 0.13 | 0.07 | -0.13 | -0.04 | 0.06 | 0.07 | 0.06 | -0.09 |
| Balance Sheet | |||||||||||
| Total Assets | 3.15B | 3.65B | 3.53B | 3.58B | 3.46B | 3.70B | 3.54B | 3.78B | 3.71B | 4.00B | 3.79B |
| Total Liabilities | 2.08B | 1.86B | 1.63B | 1.73B | 1.54B | 1.88B | 1.87B | 2.04B | 1.91B | 2.15B | 2.00B |
| Shareholders' Equity | 882M | 1.59B | 1.69B | 1.67B | 1.70B | 1.59B | 1.48B | 1.54B | 1.59B | 1.64B | 1.57B |
| Cash & Short-term Investments | 177M | 454M | 377M | 258M | 213M | 175M | 126M | 194M | 154M | 139M | 119M |
| Total Debt | 831M | 717M | 745M | 843M | 814M | 1.01B | 990M | 773M | 797M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -32.4M | 159M | 205M | 164M | 200M | 263M | 184M | 218M | 128M | 41.6M | - |
| Capital Expenditure | 55.9M | 128M | 132M | 144M | 138M | 68.5M | 64.3M | 67.3M | 113M | 99.9M | 150M |
| Free Cash Flow | -88.3M | 30.6M | 73.5M | 20.5M | 61.9M | 195M | 119M | 151M | 14.2M | -58.3M | 134M |
| Ratios | |||||||||||
| ROE | 3.1% | 0.9% | 5.5% | 5.7% | 3.3% | -6.3% | -2.0% | 3.2% | 3.4% | 2.9% | -4.1% |
| ROA | 0.9% | 0.4% | 2.6% | 2.7% | 1.6% | -2.7% | -0.9% | 1.3% | 1.4% | 1.2% | -1.7% |
| Net Profit Margin | 1.9% | 0.8% | 5.3% | 4.5% | 3.1% | -5.1% | -1.5% | 2.1% | 2.1% | 2.0% | -3.2% |
| Debt to Equity | 0.94x | 0.45x | 0.44x | 0.50x | 0.48x | 0.63x | 0.67x | 0.50x | 0.50x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Centergate Technologies Holding Co Ltd dividends
- Dividend yield
- 0.17%
- Forward dividend
- 0.02 CNY
- Payout ratio
- 10.2%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 4.91M | 0.01 | 10.2% |
| 2024 | CNY 28.8M | 0.04 | 53.8% |
| 2023 | CNY 32.8M | 0.04 | 67.6% |
| 2022 | CNY 40.6M | 0.05 | - |
| 2021 | CNY 36.0M | 0.05 | - |
| 2020 | CNY 57.0M | 0.08 | 103.0% |
| 2019 | CNY 54.1M | 0.07 | 56.8% |
| 2018 | CNY 61.7M | 0.08 | 66.2% |
| 2017 | CNY 113M | 0.15 | 794.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 11.6:10 on Jan 9, 2007.
Who owns Beijing Centergate Technologies Holding Co Ltd
- Insiders 35.59%
- Institutions 0.06%
- Public & others 64.35%
- Shares outstanding 753M
- Free float 506M
Beijing Centergate Technologies Holding Co Ltd company profile
- Company name
- Beijing Centergate Technologies Holding Co Ltd
- Ticker
- 000931.SHE
- ISIN
- CNE000001030
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Real Estate Management & Development
- Employees
- 2,267
- Fiscal year end
- December
- Address
- Building B, Pengrun Building, Room 2208, Beijing, China, 100016
- Phone
- 86 10 5776 8899
- Website
- centek.com.cn
About Beijing Centergate Technologies Holding Co Ltd
Beijing Centergate Technologies (holding) Co., Ltd. engages in the production and sale of topical reagents, tablets, injections in China. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Naltrexone Hydrochloride tablets and injections to block the pharmacological effects of exogenous opioids; Acetaminophen and oxycodone tablets and injections for the treatment of moderate to severe pain; tramadol hydrochloride tablets and injections to treat pain in adults; aprolol hydrochloride for the treatment of hypertension, angina pectoris, tachycardia-induced arrhythmia, and tremor; buspirone hydrochloride tablets to treat various anxiety disorders; oxycodone hydrochloride extended-release tablets; and Ambroxol hydrochloride injection for the treatment of acute exacerbations of chronic bronchitis, wheezing bronchitis, and bronchial asthma. It also provides Febuxostat tablets for the treatment of hyperuricemia; Bromhexine Hydrochloride injection to treat asthma, bronchiectasis, and silicosis; Metoprolol succinate raw material; Bisoprolol Amlodipine tablets for hypertension; Sitagliptin/Metformin tablets are used for type 2 diabetes patients; Bisoprolol fumarate tablets for the treatment of hypertension, coronary, and artery diseases; and Tropanestone mesylate injection for the treatment of nausea and vomiting. In addition, the company offers Sildenafil lozenges, Benzyl nonyl hydrochloride tablets, Oxycodone Hydrochloride injection, Bifonazole cream, Huperzine A tablets, Wujia Biochemical capsules, Lactobacillus tablets, Tramadol acetaminophen tablets, Tramadol hydrochloride raw material, Clindamycin phosphate to treat bacterial vaginosis, Piracetam injection, Acanthopanax senticosus, Benidipine Hydrochloride for the treatment of hypertension and angina pectoris, Glipizide Dispersible tablets, and Compound Pancreatic Enzyme powders. Beijing Centergate Technologies (holding) Co., Ltd. was founded in 1999 and is based in Beijing, China.
Beijing Centergate Technologies Holding Co Ltd management
7- Mr. Zhanjun HouPresident & Non-Independent Director · born 1972
- Mr. Xuewu SongVP & CFO · born 1972
- Mr. Bin LiVice President · born 1970
- Ms. Xiujun FanVice President · born 1976
- Mr. Dehui CheVice President · born 1970
- Ms. Xihong WangVice President · born 1971
- Mr. Zhiyu HuangVP & Board Secretary · born 1975